New therapeutic agents for the treatment of bone diseases

Bibliography

• CHRISTODOULOU C, COOPER C: What is osteoporosis? Postgrad. Med. J. (2003) 79:133–138.
   Google Scholar
• MELTON LJ 3rd, JOHNELL O, LAU E, MAUTALEN CA, SEEMAN E: Osteoporosis and the global competition for health care resources. J. Bone Miner. Res. (2004) 19:1055–1058.
   PubMed Web of Science ®Google Scholar
• VAN STAA TP, LEUFKENS HG, COOPER C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. (2002) 13:777–787.
   PubMed Web of Science ®Google Scholar
• •This analysis provides important insight into the incidence and severity of corticosteroid-induced bone loss.
   Google Scholar
• PFEILSCHIFTER J, DIEL IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol. (2000) 18:1570–1593.
   PubMed Web of Science ®Google Scholar
• ••This comprehensive review summarised thecurrent understanding of CTIBL and explains the expanding problems it may present.
   Google Scholar
• MERCADANTE S: Malignant bone pain: pathophysiology and treatment. Pain (1997) 69:1–18.
   PubMed Web of Science ®Google Scholar
• WEINFURT KP, CASTEL LD, LI Y, TIMBIE JW, GLENDENNING GA, SCHULMAN KA: Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med. Care (2004) 42:164–175.
   PubMed Web of Science ®Google Scholar
• WEINFURT KP, LI Y, CASTEL LD et al.: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. (2005) 16:579–584.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE: Skeletal complications of malignancy. Cancer (1997) 80(Suppl.):1588–1594.
   Google Scholar
• ••This review summarises the prevalence ofbone lesions in patients with cancer and describes the skeletal complications that often result.
   Google Scholar
• BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. (1998) 16:593–602.
   PubMed Web of Science ®Google Scholar
• •This trial established the long-term safety and efficacy of pamidronate in patients with osteolytic bone lesions from multiple myeloma.
   Google Scholar
• ROSEN LS, GORDON D, TCHEKMEDYIAN NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer (2004) 100:2613–2621.
   PubMed Web of Science ®Google Scholar
• ••This 21-month extension of the 9-monthcore trial established the long-term efficacy and safety of zoledronic acid in patients with bone metastases secondary to non-small cell lung cancer and other solid tumours.
   Google Scholar
• SAAD F, GLEASON DM, MURRAY R et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Nail. Cancer Inst. (2004) 96:879–882.
   PubMed Web of Science ®Google Scholar
• ••This 24-month extension of the 15-monthcore trial established the long-term efficacy and safety of zoledronic acid in patients with bone metastases secondary to advanced prostate cancer.
   Google Scholar
• LIPTON A, THERIAULT RL, HORTOBAGYI GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer (2000) 88:1082-1090.
   Google Scholar
• •This trial established the long-term safety and efficacy of pamidronate in patients with osteolytic lesions from breast cancer.
   Google Scholar
• SAAD F, GLEASON D, MURRAY R et aL: Zoledronic acid improves markers of bone resorption and bone formation in prostate cancer patients with osteoblastic bone metastases. Presented at: 3rd North American Symposium: Skeletal Complications of Malignancy. Bethesda, Maryland, USA (25–27 April 2002).
   Google Scholar
• PARFITT AM: Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Can. J. Oncol. (1995) 5\(Suppl. 1):1–10.
   Google Scholar
• BERRUTI A, DOGLIOTTI L, GORZEGNO Get al.: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem. (1999) 45\(Pt 1):1240–1247.
   Google Scholar
• MAILLEFERT JF, SIBILIA J, MICHEL F, SAUSSINE C, JAVIER RM, TAVERNIER C: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. UroL (1999) 161:1219-1222.
   Google Scholar
• DANIELL HW, DUNN SR, FERGUSON DW, LOMAS G, NIAZI Z, STRATTE PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. UroL (2000) 163:181–186.
   PubMed Web of Science ®Google Scholar
• BERRUTI A, DOGLIOTTI L, TERRONE C et al.: Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. UroL (2002) 167:2361–2367.
   PubMed Web of Science ®Google Scholar
• RASHID M, KHAIRI A, JOHNSTON C JR: Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). Clin. Orthop. Relat. Res. (1977):94–105.
   PubMed Web of Science ®Google Scholar
• FLEISCH HA: Bisphosphonates: preclinical aspects and use in osteoporosis. Ann. Med. (1997) 29:55–62.
   PubMed Web of Science ®Google Scholar
• SINGER FR, MINOOFAR PN: Bisphosphonates in the treatment of disorders of mineral metabolism. Adv. EndocrinoL Metab. (1995) 6:259–288.
   PubMedGoogle Scholar
• CAUZA E, ETEMAD M, WINKLER F et al.: Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J. Clin. Pharm. Ther. (2004) 29:431–436.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N EngL J. Med. (2002) 346:653–661.
   PubMed Web of Science ®Google Scholar
• •This trial reported that a single infusion of zoledronic acid reduced bone resorption levels for 1 year.
   Google Scholar
• FLEISCH H: Bisphosphonates: mechanisms of action. Endocr. Rev. (1998) 19:80–100.
   PubMed Web of Science ®Google Scholar
• NOVARTIS PHARMACEUTICALS CORPORATION: AREDIA®: [package insert]. Pamidronate disodium prescribing information. East Hanover, NJ, USA (2002).
   Google Scholar
• BODY JJ, BARTL R, BURCKHARDT Pet al.: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J. Clin. Oncol. (1998) 16:3890–3899.
   Google Scholar
• PECHERSTORFER M, HERRMANN Z, BODY JJ et al.: Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Clin. Oncol. (1996) 14:268–276.
   Web of Science ®Google Scholar
• MAJOR P, LORTHOLARY A, HON J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19:558–567.
   PubMed Web of Science ®Google Scholar
• ••Pivotal trial of zoledronic acid for thetreatment of HCM.
   Google Scholar
• MAJOR PP, LIPTON A, BERENSON J, HORTOBAGYI G: Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer (2000) 88:6–14.
   PubMed Web of Science ®Google Scholar
• •This review summarises the benefits and drawbacks of oral bisphosphonates for malignant bone disease.
   Google Scholar
• LIPTON k Treatment of skeletal complications in cancer patients: focus on bisphosphonates. Oncology Special Edition (2004) 7:59–64.
   Google Scholar
• LUCKMAN SP, HUGHES DE, COXON FP, GRAHAM R, RUSSELL G, ROGERS MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13:581–589.
   PubMed Web of Science ®Google Scholar
• •Key paper describing the pharmacological effect of nitrogen-containing bisphosphonates.
   Google Scholar
• ROGERS MJ, FRITH JC, LUCKMAN SP et al.: Molecular mechanisms of action of bisphosphonates. Bone (1999) 24(Suppl.):73S–795.
   Google Scholar
• RUSSELL RG, ROGERS MJ, FRITH JC et al.: The pharmacology of bisphosphonates and new insights into their mechanisms of action./ Bone Miner. Res. (1999) 14\(Suppl. 2):53–65.
   Google Scholar
• ROGERS MJ, GORDON S, BENFORD HL et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 88:2961–2978.
   PubMedGoogle Scholar
• LUCKMAN SP, COXON FP, EBETINO FH, RUSSELL G, ROGERS MJ: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J. Bone Miner. Res. (1998) 13:1668–1678.
   PubMed Web of Science ®Google Scholar
• OLIFF A: Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta (1999) 1423:C19–C30.
   PubMed Web of Science ®Google Scholar
• ZHANG FL, CASEY PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. (1996) 65:241–269.
   PubMed Web of Science ®Google Scholar
• GREEN JR, CLEZARDIN P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol (2002) 25\(Suppl. 1):53–59.
   Google Scholar
• HUGHES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478–1487.
   PubMed Web of Science ®Google Scholar
• SELANDER KS, MONKKONEN J, KARHUKORPI EK, HARKONEN P, HANNUNIEMI R, VAANANEN HK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. MoL Pharmacol (1996) 50:1127–1138.
   PubMed Web of Science ®Google Scholar
• BENFORD HL, MCGOWAN NW, HELFRICH MH, NUTTALL ME, ROGERS MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone (2001) 28:465–473.
   PubMed Web of Science ®Google Scholar
• SENARATNE SG, PIRIANOV G, MANSI JL, ARNETT TR, COLSTON KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer (2000) 82:1459–1468.
   PubMed Web of Science ®Google Scholar
• PATERSON AH, POWLES TJ, KANIS JA, MCCLOSKEY E, HANSON J, ASHLEY S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol (1993) 11:59–65.
   PubMed Web of Science ®Google Scholar
• KRISTENSEN B, EJLERTSEN B, GROENVOLD M, HEIN S, LOFT H, MOURIDSEN HT: Oral clodronate in breast cancer patients with bone metastases: a randomized study./ Intern. Med. (1999) 246:67–74.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol (1998) 16:2038–2044.
   Google Scholar
• THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group./ Clin. Oncol (1999) 17:846–854.
   Google Scholar
• •This trial established pamidronate as a standard of care in patients who are receiving cytotoxic chemotherapy for breast cancer with osteolytic bone metastases.
   Google Scholar
• ROSEN LS, GORDON D, KAMINSKI M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer (2003) 98:1735–1744.
   PubMed Web of Science ®Google Scholar
• ••This 2-year extension of the 13-monthcore trial established that zoledronic acid is more effective than pamidronate in reducing the risk of skeletal morbidity in the overall population of patients with breast cancer or multiple myeloma and in the subset of patients with breast cancer. Zoledronic acid was safe for long-term use in this setting.
   Google Scholar
• LANGSTON AL, RALSTON SH: Management of Paget's disease of bone. Rheumatology (Oxford) (2004) 43:955–959.
   PubMed Web of Science ®Google Scholar
• ••This review summarises the benefits andlimitations of existing therapies for Paget's disease.
   Google Scholar
• PONDEL M: Calcitonin and calcitonin receptors: bone and beyond. Int. J. Exp. Pathol (2000) 81:405–422.
   PubMed Web of Science ®Google Scholar
• MARTIN TJ, JERUMS G, MELICK RA, XIPELL JM, ARNOTT R: Clinical, biochemical and histological observations on the effect of porcine calcitonin in Paget's disease of bone. Aust. N Z. J Med. (1977) 7:36–43.
   PubMedGoogle Scholar
• O'DOHERTY DP, BICKERSTAFF DR, MCCLOSKEY EV, ATKINS R, HAMDY NA, KANIS JA: A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin. Sci. (Lond.) (1990) 78:215–219.
   PubMed Web of Science ®Google Scholar
• EL SAIVIMAA M, LINTHICUM FH JR, HOUSE HP, HOUSE JW: Calcitonin as treatment for hearing loss in Paget's disease. Am. J. Otol (1986) 7:241–243.
   PubMedGoogle Scholar
• SIRIS ES, CANFIELD RE, JACOBS TP, STODDART KE, SPECTOR PJ: Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. Metab. Bone Dis. Relat. Res. (1981) 3:301–308.
   PubMedGoogle Scholar
• MILLER PD, BROWN JP, SIRIS ES, HOSEYNI MS, AXELROD DW, BEKKER PJ: A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am. j Med. (1999) 106:513–520.
   Google Scholar
• •This trial demonstrated the superiority of the nitrogen-containing bisphosphonate risedronate compared with etidronate in reducing bone metabolism in patients with Paget's disease.
   Google Scholar
• O'DOHERTY DP, GERTZ BJ, TINDALE W, SCIBERRAS DG, SURVILL Ti KANIS JA: Effects of five daily 1 h infusions of alendronate in Paget's disease of bone./ Bone Miner. Res. (1992) 7:81–87.
   PubMed Web of Science ®Google Scholar
• KHAN SA, VASIKARAN S, MCCLOSKEY EV et al: Alendronate in the treatment of Paget's disease of bone. Bone (1997) 20:263–271.
   PubMed Web of Science ®Google Scholar
• •This article reviews clinical trial data on the efficacy and safety of alendronate in patients with Paget's disease.
   Google Scholar
• GARNERO P, CHRISTGAU S, DELMAS PD: The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone (2001) 28:461–464.
   PubMed Web of Science ®Google Scholar
• GARNERO P, GINEYTS E, SCHAFFER AV SEAMAN J, DELMAS PD: Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. (1998) 41:354–360.
   PubMed Web of Science ®Google Scholar
• MILLER P, BROWN J, HOSKING D et al.: Zoledronic acid produces higher and more rapid therapeutic response rates versus risedronate in patients with Paget's Disease. Proc. Osteoporos. Int. (2004) Abstract OC48.
   Google Scholar
• WALSH JP, WARD LC, STEWART GO et al.: A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone (2004) 34:747–754.
   PubMed Web of Science ®Google Scholar
• HOSKING DJ, MILLER P, BROWN J et al.: Zoledronic acid produces greater clinically relevant reductions in biochemical markers in patients with Paget's disease versus risedronate. Proceedings of the 26th Annual Meeting of the American Society for Bone and Mineral Research. Washington, USA (1–5 October 2004).
   Google Scholar
• CHESNUT CH 3rd, MCCLUNG MR, ENSRUD KE et al.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am. J. Med. (1995) 99:144–152.
   Google Scholar
• MAZZUOLI GF, PASSERI M, GENNARI Get al.: Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int. (1986) 38:3–8.
   Google Scholar
• HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone- (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. EndocrinoL Metab. (2003) 88:5212–5220.
   PubMed Web of Science ®Google Scholar
• SCHIMMER RC, BAUSS F: Effect of dailyand intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three Phase II studies. Clin. Ther. (2003) 25:19–34.
   PubMed Web of Science ®Google Scholar
• CHESNUT CH III, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19:1241–1249.
   PubMed Web of Science ®Google Scholar
• BLACK DM, ROSARIO-JANSEN T, DELMAS PD et al.: HORIZON-pivotal fracture trial: unique design of a randomized, placebo-controlled trial to examine the effect of annual infusion of zoledronic acid (5 mg) on hip and spine fracture reduction. International Osteoporosis Foundation World Congress on Osteoporosis. Rio de Janeiro, Brazil (14–18 May 2004) [abstract P366M0]. Osteoporos. Int. (2004) 15\(Suppl. 1):599.
   Google Scholar
• THERIAULT RL: Pathophysiology and implications of cancer treatment-induced bone loss. Oncology (Huntingt.) (2004) 18\(Suppl. 3):11–15.
   Google Scholar
• ••This review summarises the mechanisms ofCTIBL and provides important insight into associated clinically relevant effects.
   Google Scholar
• BAUM M, BUDZAR AU, CUZICK J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131-2139. Erratum: Lancet (2002) 360:1520.
   Google Scholar
• •This trial compares the efficacy and safety of anastrozole alone versus anastrozole and tamoxifen combination adjuvant therapy for early breast cancer.
   Google Scholar
• MICHAELSON D, MARUJO RR, SMITH MR: Cross-sectional analysis of markers of osteoblast and osteoclast activity in men with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:379 (Abstract 1521).
   Google Scholar
• DELMAS PD, BALENA R, CONFRAVREUX E, HARDOUIN C, HARDY P, BREMOND A: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. Clin. Oncol. (1997) 15:955–962.
   Web of Science ®Google Scholar
• •This trial demonstrated that the nitrogen-containing bisphosphonate risedronate significantly reduces bone loss compared with placebo in women with artificial menopause from breast cancer chemotherapy.
   Google Scholar
• SMITH MR, MCGOVERN FJ, ZIETMAN AL et al.: Pamidronate to prevent bone loss during androgen- deprivation therapy for prostate cancer. N Engl. J. Med. (2001) 345:948–955.
   PubMed Web of Science ®Google Scholar
• SMITH MR, EASTHAM J, GLEASON DM, SHASHA D, TCHEKMEDYIAN S, ZINNER N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer./ Urol (2003) 169:2008–2012.
   Google Scholar
• •This trial established that zoledronic acid can increase BMD in men during ADT for early prostate cancer, a treatment that can lead to severe bone loss.
   Google Scholar
• GNANT M, JAKESZ R, MLINERITSCH B et al.: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Proc. Breast Cancer Res. Treat. (2004) Abstract.
   Google Scholar
• •This trial demonstrated that severe bone loss can occur in premenopausal women treated with hormonal therapy for breast cancer, and that zoledronic acid can prevent bone loss in this setting. Furthermore, the results from this trial illustrate that tamoxifen does not preserve bone mass in premenopausal patients.
   Google Scholar
• HORTOBAGYI GN, THERIAULT R1,, PORTER Let al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl. J. Med. (1996) 335:1785–1791.
   Google Scholar
• •This trial established pamidronate as a standard of care in patients who are receiving cytotoxic chemotherapy for breast cancer with osteolytic bone metastases.
   Google Scholar
• BERENSON JR, LICHTENSTEIN A, PORTER Let al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl. J. Med. (1996) 334:488–493.
   Google Scholar
• •This trial established pamidronate as a standard of care in patients with osteolytic lesions from multiple myeloma.
   Google Scholar
• ROSS JR, SAUNDERS Y, EDMONDS PM et al.: A systematic review of the role of bisphosphonates in metastatic
   Google Scholar
• •• disease. Health TechnoL Assess. (2004) 8:1–176.
   Google Scholar
• MAJOR PP, COOK R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am. J. Clin. Oncol. (2002) 25\(Suppl. 1):S10–S18.
   Google Scholar
• BODY JJ, DIEL IJ, LICHINITSER MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. (2003) 14:1399–1405.
   PubMed Web of Science ®Google Scholar
• BODY JJ, DIEL IJ, LICHINITZER MRet al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer (2004) 90:1133–1137.
   Google Scholar
• •This pooled analysis of two clinical trials demonstrates that oral ibandronate can provide significant benefits for patients with bone metastases from breast cancer.
   Google Scholar
• BODY JJ, DIEL IJ, BELL R et ell.: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain (2004) 111:306–312.
   Google Scholar
• ROSEN LS, GORDON D, KAMINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7:377–387.
   PubMed Web of Science ®Google Scholar
• •This 13-month trial established that the efficacy and safety of zoledronic acid are at least comparable to those of pamidronate in patients with breast cancer or multiple myeloma.
   Google Scholar
• ROSEN LS, GORDON DH, DUGAN W JR et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 100:36–43.
   Google Scholar
• COLEMAN RE, COOK R, MAJOR P et al.: Why is zoledronic acid (Z) superior to pamidronate (P) for bone metastases from breast cancer (BC) but equivalent in multiple myeloma (MM)? [abstract]. Proc. Am. Soc. Clin. OncoL (2003) Abstract 187.
   Google Scholar
• KOHNO N, AOGI K, MINAMI H et aL: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. (2005) 23(15):3314–3321.
   PubMed Web of Science ®Google Scholar
• ••This placebo-controlled trial reported thatzoledronic acid provides significant benefits in women with bone metastases from breast cancer, and benefits include significant and durable pain reduction.
   Google Scholar
• SMITH JA JR: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol. (1989) 141:85–87.
   PubMed Web of Science ®Google Scholar
• ELOMAA I, KYLMALA T, TAMMELA T et al.: Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int. UroL NephroL (1992) 24:159–166.
   PubMed Web of Science ®Google Scholar
• KYLMALA T, TAUBE T, TAMMELA TL, RISTELI L, RISTELI J, ELOMAA I: Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind placebo-controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76:939–942.
   Google Scholar
• STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. (1997) 17:4717–4721.
   PubMed Web of Science ®Google Scholar
• ERNST DS, TANNOCK IF, WINQUIST EW et aL: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol. (2003) 21:3335–3342.
   PubMed Web of Science ®Google Scholar
• DEARNALEY DP, SYDES MR, MASON MD et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PROS Trial). J. NatL Cancer Inst. (2003) 95:1300–1311.
   PubMed Web of Science ®Google Scholar
• CLARKE NW, HOLBROOK IB, MCCLURE J, GEORGE NJ: Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br. J. Cancer (1991) 63:420–423.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, SMITH MR, SEAMAN JJ, PETRONE S, KOWALSKI MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. (2003) 21:4277–4284.
   PubMed Web of Science ®Google Scholar
• HEIDENREICH A, ELERT A, HOFMANN R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. (2002) 5:231–235.
   PubMed Web of Science ®Google Scholar
• SAAD F, GLEASON DM, MURRAY R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Nail. Cancer Inst. (2002) 94:1458–1468.
   PubMed Web of Science ®Google Scholar
• ••Pivotal clinical trial demonstrating theefficacy and safety of zoledronic acid compared with placebo in patients with prostate cancer at 15 months.
   Google Scholar
• ROSEN LS: Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin. Oncol. (2002) 29\(Suppl. 21):28–32.
   Google Scholar
• LIPTON A, ZHENG M, SEAMAN J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer (2003) 98:962–969.
   PubMed Web of Science ®Google Scholar
• •Subset analysis showing that zoledronic acid has significant clinical benefit in patients with bone metastases from renal cell carcinoma.
   Google Scholar
• NOVARTIS PHARMACEUTICALS CORPORATION: ZOMETA®: [package insert]. Zoledronic acid injection prescribing information. East Hanover, NJ, USA (2005).
   Google Scholar
• MARX RE: Pamidronate (Aredia) and zoledronate (ZOMETA) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. (2003) 61:1115–1118.
   PubMed Web of Science ®Google Scholar
• WANG J, GOODGER NM, POGREL Mk Osteonecrosis of the jaws associated with cancer chemotherapy. J. Oral. Maxillofac. Surg. (2003) 61:1104–1107.
   PubMed Web of Science ®Google Scholar
• POGREL MA: Bisphosphonates and bone necrosis. J. Oral. Maxillofac. Surg (2004) 62:391–392.
   PubMed Web of Science ®Google Scholar
• MIGLIORATI CA: Bisphosphanates and oral cavity avascular bone necrosis. J. Clin. Oncol. (2003) 21:4253–4254.
   PubMed Web of Science ®Google Scholar
• CARTER GD, GOSS AN: Bisphosphonates and avascular necrosis of the jaws. Aust. Dent. j ( 2003) 48:268.
   PubMed Web of Science ®Google Scholar
• RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg (2004) 62:527–534.
   PubMed Web of Science ®Google Scholar
• HEI YJ: Future directions for zoledronic acid and new agents for the treatment of bone metastases. Eur. Urol. (2004) 3:55–62.
   Web of Science ®Google Scholar
• ••This review summarises investigationaltherapies for bone metastases from prostate cancer.
   Google Scholar
• YAIVIASHITA DS, DODDS RA: Cathepsin K and the design of inhibitors of cathepsin K. Curr. Pharm. Des. (2000) 6:1–24.
   PubMed Web of Science ®Google Scholar
• STROUP GB, LARK MW, VEBER DF et al.: Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. (2001) 16:1739–1746.
   PubMed Web of Science ®Google Scholar
• MUNDY GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer (2002) 2:584–593.
   PubMed Web of Science ®Google Scholar
• •This review summarises the pathophysiology and possible complications of malignant bone disease and discusses available therapeutic interventions.
   Google Scholar
• ZHANG J, DAI J, QI Y et ell.: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. (2001) 107:1235–1244.
   Google Scholar
• YACCOBY S, PEARSE RN, JOHNSON CL, BARLOGIE B, CHOI Y, EPSTEIN J: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol (2002) 116:278–290.
   PubMed Web of Science ®Google Scholar
• MORONY S, CAPPARELLI C, SAROSI I, LACEY DL, DUNSTAN CR, KOSTENUIK PJ: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. (2001) 61:4432–4436.
   PubMed Web of Science ®Google Scholar
• BODY JJ, GREIPP P, COLEMAN RE et al.: A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 97(Suppl.):887–892.
   Google Scholar
• BEKKER PJ, HOLLOWAY DL, RASMUSSEN AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
   Google Scholar
• J. Bone Miner. Res. (2004) 19:1059–1066.
   Google Scholar
• NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944–949.
   PubMed Web of Science ®Google Scholar
• YIN JJ, MOHAMMAD KS, KAKONEN SM et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA (2003) 100:10954–10959.
   PubMed Web of Science ®Google Scholar
• NELSON JB, NABULSI AA, VOGELZANG NJ et al.: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. j Urol. (2003) 169:1143–1149.
   PubMed Web of Science ®Google Scholar
• VIERECK V, EMONS G, LAUCK V et ell.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. (2002) 291:680–686.
   PubMed Web of Science ®Google Scholar
• BERENSON J, HIRSCHBERG R: Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist (2004) 9:319–329.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN: Novel approaches to the management of bone metastases in patients with breast cancer. Semin. Oncol (2002) 29\(Suppl. 11):134–144.
   Google Scholar
• BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. j Clin. Oncol. (2002) 20:3719-3736. This manuscript summarises the ASCO guidelines for bisphosphonate therapy in patients with multiple myeloma.
   Google Scholar
• SAAD F, SCHULMAN CC: Role of bisphosphonates in prostate cancer. Eur. Urol. (2004) 45:26–34.
   PubMed Web of Science ®Google Scholar
• HILLNER BE, INGLE JN, CHLEBOWSKI RT et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [Published erratum in: J. Clin. Oncol (2004) 22:1351].j Clin. Oncol. (2003) 21:4042-4057. This manuscript summarises the ASCO guidelines for bisphosphonate therapy in patients with breast cancer.
   Google Scholar
• DELEA T, JAMES M, LISS M et al.: Effects of skeletal complications on total medical care costs in women with bone metastases of breast cancer [abstract]. Proc. Bone (2004) 34(Suppl.):586 (Abstract 68).
   Google Scholar
• DELEA T, MCKIERNAN J, LISS M et al.: Cost of skeletal complications in patients with multiple myeloma. Presented at: LY-th Annual International Workshop on Multiple Myeloma. Salamanca, Spain (23–27 May 2003).
   Google Scholar
• DESHARNAIS CASTEL L, BAJWA K, MARKLE JP, TIMBIE JW, ZACKER C, SCHULMAN KA: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support. Care Cancer (2001) 9:545–551.
   PubMed Web of Science ®Google Scholar
• SAAD F, GUISE T, HUSSAIN A et al.: The role of intravenous bisphosphonates in the management of prostate cancer: treatment guidelines. Am. J. Urol. Rev. (2004) 2\(Suppl. 2):9–15.
   Google Scholar
• ALI SM, ESTEVA FJ, HORTOBAGYI G et al.: Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Clin. Oncol. (2001) 19:3434–3437.
   Web of Science ®Google Scholar
• LIPTON A: Bisphosphonate therapy in the oncology setting. Expert Opin. Emerg-. Drugs (2003) 8:469–488.
   PubMedGoogle Scholar
• http://www.cureresearch.com/p/pagetbone/ prevalence.htm Cure Research website - Prevalence and incidence of Paget's disease of bone (2005).
   Google Scholar
• http://www.paget.org/Register/index.asp The Paget Foundation website factsheet (2005).
   Google Scholar
• http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-003256,00.asp American Society of Clinical Oncology website (2003).
   Google Scholar